Kodiak Sciences Inc. (KOD) NASDAQ

39.61

+0.12(+0.30%)

Updated at May 13 04:00PM

Currency In USD

About Privacy Policy Contact us Terms & Conditions

Kodiak Sciences Inc.

Address

1200 Page Mill Road

Palo Alto, CA 94304

United States of America (the)

Phone

650 281 0850

Website

https://kodiak.com

Sector

Healthcare

Industry

Biotechnology

Employees

109

First IPO Date

October 04, 2018

Key Executives

Name	Title	Pay	Year Born
Victor Perlroth	Co-Founder, Chairman, Chief Executive Officer & President	1.58M	1974
Hong Liang	Senior Vice President of Development	300,709	1972
John A. Borgeson	Executive Vice President, Chief Financial Officer & Secretary	937,157	1963
Almas Qudrat	Chief Quality Officer	0	N/A
Dolly S. Chang	Chief Scientific Officer	0	N/A
J. Pablo Velazquez-Martin	Chief Medical Officer	0	N/A
Stephen Raillard	Senior Vice President of Chemical Development & Manufacturing	0	N/A
Laurent Ducry	Senior Vice President of Biologics Development & Manufacturing	0	N/A
Laurent Ducay	Senior Vice President of Biologics Development & Manufacturing	0	N/A
Wayne To	Chief Technology Officer	0	N/A

Description

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.